# About Semax Compound: An Editorial Field Log | Semax

> About Semax Compound — an independent editorial project that publishes plain-English summaries of the peer-reviewed Semax research literature. Not a clinic, not a vendor, no medical advice.

An independent editorial field log of the published Semax research — what it is, what it is not, and how it is sourced.

## What this project is

Semax Compound is an independent editorial project that publishes summaries of the peer-reviewed research literature on Semax. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The "compound" in the name is editorial framing — a position we occupy relative to the literature, treating Semax as a compound to be observed and logged, not a product to be moved. Think of the site as a field notebook: the published record on one molecule, read carefully, tabulated, and kept honest about its own limits.

## How we read the record

Our method is plain. We summarize what studies measured — the species, the dose, the route, the outcome — and we attach a citation to every quantitative claim so a reader can check it. We keep three things visibly separate: established findings, mechanistic inferences, and community reports. The community's experience with Semax is logged on the effects page and labeled anecdotal throughout, never blended into the study data.

We also try to be honest about what the literature cannot support. Most Semax research is preclinical and Russian in origin, the human studies are few, and there are no Western controlled trials. We say so, repeatedly, because a fair reading of this compound requires holding the genuine findings and the genuine gaps in view at the same time.

## Is semax legal

**Is semax legal** depends entirely on where you are, and this is a factual status note, not advice. In Russia and Ukraine, Semax is an approved prescription drug, registered for ischemic stroke, transient ischemic attack, cognitive impairment, and optic-nerve disease, and it sits on Russia's List of Vital and Essential Drugs.

Outside those countries it has no such status. In the United States it is not FDA-approved for any human indication and is handled as an unscheduled research chemical as of 2025; it is not EMA-approved in Europe. On anti-doping: Semax does not appear by name on the 2025 WADA Prohibited List, but as a non-approved substance it may fall under the catch-all S0 category, so athletes under anti-doping rules should consult GlobalDRO and the relevant authorities. Regulatory status changes; treat this as a starting point, not legal counsel.

---

A field log of the published Semax research — observed and tabulated, never prescribed.